Study S001507

A Randomized, Placebo-controlled, Double Blind Trial of Semaglutide 1mg (Ozempic®) on Regression to Normoglycemia in WomEn with a Recent History of Gestational DiabETes Mellitus: the SWEET Study

ClinicalTrials.gov record

Registration

Registration: NCT04873050
Acronym: SWEET
Study type: INTERVENTIONAL
Allocation: RANDOMIZED
Phase: PHASE4
Masking: QUADRUPLE
Status: RECRUITING
Enrollment: 102
Start: 2022-01-13
Primary completion: 2026-01-01
Lead sponsor: Woman's
Conditions: Pre Diabetes; Postpartum Disorder
Interventions: DRUG:Semaglutide Pen Injector [Ozempic]; DRUG:Placebo semaglutide pen injector
Results posted: FALSE
Individual participant data sharing: NO

Registered primary outcomes

Regression to normoglycemia [After 24 weeks of full-dose treatment]

Linked records (0)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

No records link to this registration yet.